3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
Caroline Robert(Institut Gustave Roussy), Dirk Schadendorf(National Center for Tumor Diseases), Jeffrey J. Legos(Novartis (United States)), Jacob Schachter, Andrzej Maćkiewicz(Poznan University of Medical Sciences), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), M. Lichinitser(Apple (Israel)), Ivana Krajsová(Charles University), Florent Grange(Hôpital Lyon Sud), Daniil Stroyakovskiy(Shikoku Cancer Center), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Laurent Mortier, Bijoyesh Mookerjee(Novartis (United States)), Bogusława Karaszewska(State University of Applied Sciences in Konin), Reinhard Dummer(University Hospital of Zurich), Axel Hauschild(University Hospital Schleswig-Holstein), Kamil Drucis(Apple (Israel))
Cited by 80
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k